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ABSTRACT 
Coronary artery disease (CAD) is complication of primary or secondary hyperlipidemia. Etiological factors for hyperlipidemia 
include inherited genetic defects in low density lipoproteins (LDLs), persons accustomed to sit for prolong time, cigarette smoking, 
diabetes mellitus, and hypertension. This research work’s aim was to compare hypolipidemic features of an allopathic agent vitamin 
B-3 and another medicinal plant Z. Jujuba. Study was conducted from January 2016 to June 2016 at Jinnah Hospital Lahore, 
Pakistan. 60 male and female hyperlipidemic patients age range from 20 to 70 years were selected from the hospital. Written and 
explained consent was taken from all patients. They were divided in two groups. Group-I was advised to take two grams vitamin B-3 
in divided doses for the period of two months. Group-II was advised to take 500 grams of fruit Z. Jujuba daily for 60 days per their 
convenience. Their initial LDL and HDL cholesterol was determined by Friedwald’s formula. After 60 days therapy, their post 
treatment lipid profile was measured and mean values with ± SD were analyzed biostatistically by using SPSS version 2; 2010. 
Group-I which was on vitamin B-3 their LDL cholesterol decreased significantly and HDL cholesterol was increased significantly. 
In group-II patients LDL cholesterol was decreased significantly but HDL increase was not significant with p-value of >0.05. It was 
concluded from the research study that vitamin B-3 is potent hypolipidemic agent as compared to medicinal plant Z. Jujuba. 
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Antihyperlipidemic agents promote reduction of lipid 
levels in the plasma
1
. Some antihyperlipidemic agents 
aim to lower the levels of low-density lipoprotein (LDL) 
cholesterol, some reduce triglyceride levels, and some 
help raise the high-density lipoprotein (HDL) 
cholesterol. Reducing the LDL cholesterol, they can 
cure both the primary and secondary hyperlipidemia
2-7
. 
Vitamin B-3 or Niacin, Statins, Fibric acids, Bile Acid 
Binding Resins are main drug groups used in allopathy
8-
9
. Basic problem with use of vitamin B-3 is its dose ie; 2 
grams daily to lower cholesterol in plasma. In this dose 
it causes flushing and urticaria
10
. Statins and Fibrates 
cause rhabdomyolysis and muscular pain
11-14
. If used  
for long time, bile acid binding resins cause withdrawal 
by patient due to its metallic taste
15
.  Alternative 
hypolipidemic therapy  include medicinal herbs like Z 
Jujuba which reduce LDL cholesterol, triglycerides, 
total cholesterol and somewhat incraese HDL 
cholesterol
16
.  Active ingredients of Z Jujuba include 
colubrinic acid, zizyberenalic acid, alphitolic acid, 
alphitolic acid, betulinic acid, betulonic acid, maslinic 
acid, oleanolic acid, oleanonic acid. These Zizyphus 
jujuba compounds were examined for their antioxident 
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characteristics and proved mild to moderate free radicals 
scavenger compunds
17-20
.  Some  researchers explained 
that,  a number of compounds are present in Z. jujuba, 
including saponins, jujubosides and triterpenoic acids 
which are antioxidant  compounds  in nature
21
. In some 
meta analysis studies it was proved that major 
hypolipidemic mechanism of  Z Jujuba is that 
compounds present in the plant  bound with bile acids in 
intestine and excrete them out, thus interrupting 
enterohepatic circulation. This will cause hepatocytes to 




This work was conducted at Jinnah Hospital Lahore 
Pakistan from January 2016 to June 2016.  60 
male/female hyperlipidemic patients were enrolled for 
study. Consent was taken from all participents. Research 
work permission were approved by ethics committee of 
the hospital. Both male and female patients suffering 
from primary or secondary hyperlipidemia were 
selected. The age limit for patients was 20 to 70 years. 
Alcoholic addictive patients, cigarette smokers, habitual 
to enjoy sedentary life, with impaired liver or renal 
functions were excluded from the research study. 
Baseline Lipid Profile was determined in Biochemistry 
lab of the Hospital. Serum cholesterol was estimated by 
enzymatic method. Serum HDL-cholesterol was 
determined by using kit Cat No: 303210040 by Elli 
Tech Diagnostic, France. Chylomicrons, low density 
lipoprotein and very low density lipoprotein are 
specially precipitated with phosphotungstic acid and 
magnesium ions can then be removed by centrifugation, 
while high density lipoproteins remain in the 
supernatant. Cholesterol included in this phase is 
measured by an enzymatic method. LDL-cholesterol 
was calculated according to Friedwald formula 
(described by laralaoi J et al
21
) i.e.; LDL= TC-(TG/5+ 
HDL-C). Patients were divided in two groups, 3o 
patients in each group. Group-I was on Tab. Niacin 2 
grams daily in three divided doses. Group-II was on 
Jujube 500 grams daily in three divided times to eat. 
They were advised to take this fruit for two months.  
Mean values ± SD were taken for statistical analysis 
using SPSS version 26 (2015). Paired‘t’ test was applied 
to get significance changes in parameters before and 
after treatment. P-value >0.05 was considered as non-
significant change, p-value <0.01 was considered as 
significant and p-value <0.001 was considered as highly 
significant change in the tested parameter.  
RESULTS:  
When results were compiled after statistical analysis it 
was observed that with 60 days therapy by vitamin B-3 
LDL-cholesterol in 27 hyperlipidemic patients reduced 
29.2 mg/dl and HDL increase in this group was 7.3 
mg/dl. Three patients withdrew from the study in this 
group due to flushing in dependant parts of the body like 
hanging lower earlobes, tip of nose, testicles, fingers and 
palm of upper and lower limbs, female breast nipples. 
Basically it is not a adverse effect of vitamin B-3, rather 
it is beneficial effect of the vitamin. Because this 
flushing effect is produced by release of prostaglandin 
D-2 from endothelium of blood vessels, which causes 
vasodilatory effect on dependent parts of human body. 
Other participants were counseled carefully regarding 
vitamin B-3 dose titration, ie starting from low dose to 
therapeutic dose. In group-2 (n = 30) two months 
therapy by Z. Jujuba reduced LDL-cholesterol from 
198.82±2.17 mg/dl to 190.91±1.73 mg/dl, which is 7.9 
mg/dl change in the parameter. HDL-cholesterol in this 
group increased from 38.6±2.19 mg/dl to 41.9±2.97 
mg/dl, which is 3.3 mg/dl change in the parameter. 
Biostatistically it is non-significant change in the tested 
parameter of lipid profile.  When analyzed in percentage 
change it was seen that vitamin B-3 reduced LDL 
cholesterol 13.9 % in 27 hyperlipidemic male and 
female patients in 60 days therapy. HDL cholesterol in 
this group increased was 4.0 %. In Z. Jujuba group LDL 
cholesterol reduction in 30 male and female 
hyperlipidemic patient’s was 16.2 % and HDL 
cholesterol increase was 7.9 %.   
DISCUSSION: 
Myocardial infarction, congestive cardiac failure, 
cardiac arrhythmias, and hypertension are complications 
of coronary artery disease, which are initiated by 
formations of atherosclerotic plaques due to primary or 
secondary hyperlipidemia. We can prevent all these 
complications simply by lowering plasma lipids. LDL is 
main cause of oxidation which form foamy cells ie 
atheroma, which is sticked within inner walls of 
coronary arteries causing CAD. Simply by reducing bad 
cholesterol ie; LDL cholesterol and increasing good 
cholesterol ie; HDL cholesterol, we can prevent CAD. 
In our research study 2 grams of vitamin B-3 reduced 
LDL cholesterol in 60 days significantly. It also 
increased HDL cholesterol significantly. Palve T et al
23
 
and Salouit E et al
24
 proved same results when they used 
2 grams of vitamin B-3 in 66 hyperlipidemic patients, 
but Mao Ki et al
25
 observed lesser effects of Niacin on 
HDL cholesterol, i.e. only 4.4 %  increase in HDL 
cholesterol. Grams ET et al
26
 explained different 
mechanisms of hypolipidemic response of vitamin B-3 
on persons with different genetic code. One of the 
favorable mechanism for patients with CAD they 
described is fibrinolytic activity of vitamin B-3. In our 
results Z. Jujube fruit decreased LDL cholesterol is 7.9 
mg/dl, which is significant change in the parameter. 
HDL cholesterol is not increased significantly in our 
results with p-value of >0.05. Yulkat Y et al
27
 and 
Saloiu TL et al
28
 observed same reason of Jujube on 
LDL and HDL-cholesterol, which augment our results. 
Mekawali PO et al
29
 observed more effects of Jujube as 
we observed in low density lipoprotein cholesterol. John 
DB et al
30
 proved that if given in large amount Z Jujuba 
can lower LDL cholesterol but HDL cholesterol is not 
increased remarkably. They also mentioned mode of 
action of Jujuba that it inhibit enterohepatic circulation 
of bile, causing synthesis of bile acids in liver, instead of 
cholesterol synthesis. Many researchers do not agree to 
replace allopathy related drug regimens for 
hyperlipidemia by medicinal plants due to wide variety 
of pharmacological actions of medicinal herbs. They do 
emphasize on more research work on medicinal herbs, 
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so that patient may not suffer from synergetic effects of 
foods and these herbs. We do agree with this new slant 
on medicinal herbs. Suleman T et al
31
 described hazards 
of food-herb interaction, when patients or even 
physicians/cardiologists are not so aware about 
combined effects of these foods and herbal medicines.  
CONCLUSION:  
It was concluded at end of the research work that 
Vitamin B-3 has remarkable beneficial effects on LDL-
cholesterol reduction and HDL-cholesterol enhancing 
effect when compared with Z.  Jujuba in hyperlipidemic 
patients.  
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